CYTO
Income statement / Annual
Last year (2023), Altamira Therapeutics Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Altamira Therapeutics Ltd.'s net income was -$7.27 M.
See Altamira Therapeutics Ltd.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$0.00 |
$305,616.00 |
$63,882.00 |
$174,475.00 |
-$56,000.00 |
$1.27 M |
$322,000.00 |
-$414,000.00 |
-$67,000.00 |
$3.01 M |
Cost of Revenue |
$0.00
|
$1.44 M
|
$2.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
-$1.14 M
|
-$2.18 M
|
$174,475.00
|
-$56,000.00
|
$1.27 M
|
$322,000.00
|
-$414,000.00
|
-$67,000.00
|
$3.01 M
|
Gross Profit Ratio |
0
|
-3.72
|
-34.07
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
Research and Development Expenses |
$3.04 M
|
$19.68 M
|
$8.94 M
|
$2.86 M
|
$3.33 M
|
$6.69 M
|
$19.21 M
|
$24.78 M
|
$26.54 M
|
$17.70 M
|
General & Administrative Expenses |
$3.09 M
|
$3.52 M
|
$4.90 M
|
$2.59 M
|
$3.93 M
|
$4.26 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
Selling & Marketing Expenses |
$15,348.00
|
$2.38 M
|
$1.50 M
|
$95,663.00
|
$113,959.00
|
$43,816.00
|
$199,484.00
|
$45,649.00
|
$72,562.00
|
$237,720.00
|
Selling, General & Administrative Expenses |
$3.12 M
|
$5.90 M
|
$6.39 M
|
$2.59 M
|
$3.93 M
|
$4.26 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
Other Expenses |
$0.00
|
-$586,730.00
|
-$409,929.00
|
$0.00
|
$0.00
|
$215,720.00
|
$87,593.00
|
$34,055.00
|
$62,198.00
|
$73,434.00
|
Operating Expenses |
$6.54 M
|
$24.99 M
|
$14.92 M
|
$5.46 M
|
$7.26 M
|
$10.95 M
|
$24.36 M
|
$30.22 M
|
$30.88 M
|
$22.19 M
|
Cost And Expenses |
$6.54 M
|
$26.44 M
|
$17.16 M
|
$5.46 M
|
$7.26 M
|
$10.95 M
|
$24.36 M
|
$30.22 M
|
$30.88 M
|
$22.19 M
|
Interest Income |
$730,195.00
|
$969.00
|
$3,219.00
|
$258.00
|
$17,882.00
|
$0.00
|
$53,570.00
|
$67,565.00
|
$37,000.00
|
$52,133.00
|
Interest Expense |
$0.00
|
$911,869.00
|
$189,695.00
|
$135,151.00
|
$28,628.00
|
$1.07 M
|
$1.64 M
|
$828,547.00
|
$8,000.00
|
$49,635.00
|
Depreciation & Amortization |
$5.92 M
|
$118,887.00
|
$76,357.00
|
$20,036.00
|
$30,823.00
|
$72,713.00
|
$122,784.00
|
$97,600.00
|
$92,777.00
|
$73,984.00
|
EBITDA |
-$1.35 M |
-$17.64 M |
-$6.72 M |
-$5.26 M |
-$7.24 M |
-$10.95 M |
-$24.31 M |
-$30.06 M |
-$30.84 M |
-$22.19 M |
EBITDA Ratio |
0
|
-85.12
|
-266.43
|
-30.28
|
129.31
|
-8.65
|
-75.49
|
72.6
|
460.31
|
-7.38
|
Operating Income Ratio |
0
|
-85.51
|
-267.68
|
-30.28
|
129.63
|
-8.65
|
-75.66
|
73
|
460.87
|
-7.38
|
Total Other Income/Expenses Net |
-$1.35 M
|
-$645,643.00
|
-$1.46 M
|
-$2.94 M
|
$433,406.00
|
-$380,101.00
|
-$65,996.00
|
-$570,031.00
|
$1.17 M
|
$4.01 M
|
Income Before Tax |
-$7.27 M
|
-$26.54 M
|
-$17.37 M
|
-$8.22 M
|
-$6.83 M
|
-$11.33 M
|
-$24.43 M
|
-$30.79 M
|
-$29.71 M
|
-$18.19 M
|
Income Before Tax Ratio |
0
|
-86.84
|
-271.88
|
-47.12
|
121.89
|
-8.95
|
-75.86
|
74.38
|
443.36
|
-6.04
|
Income Tax Expense |
$0.00
|
-$10,329.00
|
$21,620.00
|
-$21,284.00
|
-$193,837.00
|
$162,177.00
|
-$17,773.00
|
-$131,055.00
|
-$84,777.00
|
-$892,177.00
|
Net Income |
-$7.27 M
|
-$26.53 M
|
-$17.39 M
|
-$8.20 M
|
-$6.63 M
|
-$11.50 M
|
-$24.41 M
|
-$30.66 M
|
-$29.71 M
|
-$18.19 M
|
Net Income Ratio |
0
|
-86.8
|
-272.22
|
-47
|
118.43
|
-9.08
|
-75.81
|
74.06
|
443.36
|
-6.04
|
EPS |
-14.81 |
-582.58 |
-525.13 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
EPS Diluted |
-14.8 |
-582.58 |
-525.13 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
Weighted Average Shares Out |
$491,000.00
|
$45,536.00
|
$33,116.00
|
$15,035.00
|
$14,545.00
|
$3,975.20
|
$1,093.50
|
$858.20
|
$807.40
|
$692.30
|
Weighted Average Shares Out Diluted |
$491,258.00
|
$45,536.00
|
$33,116.00
|
$15,035.00
|
$14,545.00
|
$3,975.20
|
$1,093.50
|
$858.20
|
$807.40
|
$692.30
|
Link |
|
|
|
|
|
|
|
|
|
|